Hepatect Cp

Hepatect Cp is a sterile solution for injection that contains human hepatitis B immunoglobulin as its active ingredient. It is supplied in a ready‑to‑use intravenous formulation and is marketed in the European Union as a prescription‑only product. The preparation provides passive immunity by delivering antibodies that can neutralize hepatitis B virus, supporting prevention of infection after exposure or liver transplantation and can be administered under medical supervision.

Hepatect Cp is indicated for several clinical situations where passive immunity against hepatitis B virus is required.

- Prevention of hepatitis B infection after known or suspected exposure to hepatitis B virus. - Post‑exposure prophylaxis for individuals who have not completed the hepatitis B vaccine series or who have an inadequate vaccine response. - Prevention of hepatitis B virus recurrence in patients undergoing liver transplantation. - Supplementation of hepatitis B immune globulin in combination with active hepatitis B vaccination for high‑risk persons.

The safety profile of Hepatect Cp reflects the typical reactions observed with human immunoglobulin products administered intravenously.

Common: - Mild fever or chills during or shortly after infusion. - Headache or dizziness. - Nausea, vomiting, or abdominal discomfort. - Local infusion site reactions such as erythema or swelling.

Serious: - Severe allergic reactions including anaphylaxis. - Acute hemolytic transfusion reaction. - Renal impairment or acute kidney injury. - Thrombotic events such as deep‑vein thrombosis.

Before administering Hepatect Cp, clinicians should evaluate patient history and monitor for specific conditions that may increase risk.

- Assess for known hypersensitivity to human immunoglobulins or any component of the formulation. - Evaluate renal function, especially in patients with pre‑existing kidney disease. - Review cardiac status, as rapid infusion may affect circulatory volume. - Consider the risk of thromboembolic events in individuals with clotting disorders or prolonged immobilization. - Use caution in pregnant or breastfeeding women; safety data are limited. - Verify hepatitis B serologic status to determine need for immunoglobulin therapy.

Hepatect Cp may interact with other medications or substances that influence immune response, coagulation, or renal function.

Avoid: - Concurrent administration of other blood products or immunoglobulins without appropriate monitoring. - Use with live vaccines, as passive antibodies may interfere with vaccine efficacy. - Simultaneous infusion of nephrotoxic drugs that could exacerbate renal impairment.

Use with caution: - Anticoagulants or antiplatelet agents, due to potential additive bleeding risk. - Diuretics, which may affect intravascular volume during infusion. - Cytotoxic chemotherapy agents, because of overlapping immunosuppressive effects.